The National Institute of Cardiology has received funding from the Medical Research Agency

The National Institute of Cardiology has received funding from the Medical Research Agency for a project titled “Application of empagliflozin in patients with hypertrophic cardiomyopathy”. The project is a non-commercial clinical study, and the agreement for its implementation has been finalized recently, officially initiating preparations for submissions to regulatory bodies.

The study, led by the National Institute of Cardiology, a leading unit in Poland specializing in the diagnosis and treatment of patients with HCM, will be conducted in collaboration with the Medical University of Białystok and international partners: the Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland in Kuopio, and the Department of Cardiology, VU University Medical Center in Amsterdam.

Share:

Facebook
Twitter
LinkedIn
Reddit